Alder BioPharmaceuticals (Nasdaq: ALDR) has submitted for US approval for eptinezumab, an investigational monoclonal antibody, and the firm’s lead candidate.
Alder has been developing the calcitonin gene-related peptide (CGRP) blocker as an option against migraines, and expects a decision within the next few months. If successful, the product could be launched at the start of next year.
The firm will be looking to compete with Amgen (Nasdaq: AMGN) and Novartis’ (NOVN: VX) Aimovig (erenumab), which was approved by the US Food and Drug Administration in May and in July in Europe last year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze